Table 2.
Univariate analyses of PFS and OS from the time of initiation of ICB-based therapy
| Variable (n) | Progression-free survival | Overall survival | ||||
| No of events | Median no of weeks (95% CI) | P value | No of events | Median no of years (95% CI) | P value | |
| Regimen | 0.103 | 0.001 | ||||
| ICB +other (17) | 10 | 15.1 (7.9–NR) | 7 | 2.2 (0.8–NR) | ||
| ICB monotherapy (9) | 6 | 5.1 (1.7–NR) | 6 | 0.8 (0.0–NR) | ||
| Ipilimumab+nivolumab (9) | 8 | 10.0 (1.1–17.9) | 8 | 0.3 (0.0–0.8) | ||
| Metastasis at diagnosis | 0.984 | 0.169 | ||||
| No (24) | 17 | 11.9 (7.6–31.9) | 13 | 1.1 (0.4–NR) | ||
| Yes (11) | 7 | 14.1 (1.7–NR) | 8 | 0.8 (0.0–1.0) | ||
| Primary site (grouped) | 0.305 | 0.066 | ||||
| CHN (15) | 9 | 17.9 (2.0–NR) | 5 | NR (0.2–NR) | ||
| Other (20) | 15 | 10.0 (5.0–34.7) | 16 | 0.8 (0.3–1.0) | ||
| Primary site (ungrouped) | 0.445 | 0.043 | ||||
| Breast (3) | 2 | 10.0 (7.9–NR) | 3 | 0.8 (0.3–NR) | ||
| CHN (15) | 9 | 17.9 (2.0–NR) | 5 | NR (0.2–NR) | ||
| Lymphedema associated (2) | 1 | 56.4 (NR–NR) | 0 | NR (NR–NR) | ||
| Radiotherapy associated (5) | 4 | 11.4 (7.4–NR) | 4 | 1.0 (0.3–NR) | ||
| Soft tissue or visceral (10) | 8 | 5.0 (1.1–37.7) | 9 | 0.5 (0.0–0.8) | ||
| Race | 0.031 | 0.040 | ||||
| Nonwhite (6) | 5 | 2.4 (1.1–NR) | 5 | 0.2 (0.0–NR) | ||
| White (29) | 19 | 14.9 (10.0–34.7) | 16 | 0.9 (0.7–NR) | ||
| Sex | 0.577 | 0.3 | ||||
| Female (19) | 14 | 11.9 (5.1–31.9) | 12 | 1.0 (0.4–NR) | ||
| Male (16) | 10 | 14.1 (3.0–NR) | 9 | 0.7 (0.2–NR) | ||
P values in bold are statistically significant per the pre-specified threshold of P < 0.05.
CHN, cutaneous angiosarcoma of the head and neck; ICB, immune checkpoint blockade; NR, not reached; OS, overall survival; PFS, progression-free survival.